Repatha, Praluent, Leqvio, Entresto, Eliquis, Xarelto and other cardiovascular medications for high cholesterol, heart failure, and stroke prevention. Find every current savings program.
We'll email you when new manufacturer programs, coupons, or savings cards become available for your medications.
No spam. Unsubscribe anytime.
Manufacturer copay programs for heart medications can save you hundreds per month. Browse all current programs and eligibility requirements.
Cardiovascular medications can cost thousands per year without assistance. PCSK9 inhibitors like Repatha and Praluent have compelling manufacturer savings programs. Anticoagulants like Eliquis and Xarelto have copay assistance for commercially insured patients.
PCSK9 Inhibitors (Repatha, Praluent, Leqvio): These high-cost cholesterol medications — often $500–$700/month — have robust manufacturer savings programs. Eligibility typically requires commercial insurance and failure on statins.
Anticoagulants (Eliquis, Xarelto, Pradaxa, Savaysa): These stroke prevention medications often have $10–$15/month copay programs for commercially insured patients, and patient assistance programs for those who qualify based on income.
Yes. Amgen provides a savings card for Repatha (evolocumab) that can reduce costs to as low as $5/month for eligible commercially insured patients. Uninsured patients may qualify for the Amgen SupportPlus patient assistance program for free medication.
With the Bristol-Myers Squibb / Pfizer Eliquis savings program, eligible commercially insured patients may pay as little as $10/month. Uninsured patients may qualify for patient assistance through the Bristol-Myers Squibb Patient Assistance Foundation.
Yes. Novartis offers the Entresto $10 copay program for eligible commercially insured patients, and the Novartis Patient Assistance Now Entresto program provides free medication for qualifying uninsured patients.
Leqvio (inclisiran) is a twice-yearly injectable PCSK9 inhibitor by Novartis for lowering LDL cholesterol. Retail cost can exceed $3,500 per injection. Novartis offers a savings program for commercially insured patients and patient assistance for qualifying uninsured patients.